Comparing Bio-Rad Laboratories (NYSE:BIO) & Prenetics Global (NASDAQ:PRE)

Prenetics Global (NASDAQ:PRE) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Prenetics Global and Bio-Rad Laboratories, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	0	0	1	0	3.00
Bio-Rad Laboratories	0	2	3	0	2.60

Prenetics Global presently has a consensus price target of $9.00, suggesting a potential upside of 61.29%. Bio-Rad Laboratories has a consensus price target of $395.20, suggesting a potential upside of 26.62%. Given Prenetics Global’s stronger consensus rating and higher probable upside, research analysts clearly believe Prenetics Global is more favorable than Bio-Rad Laboratories.

Institutional and Insider Ownership

25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 7.8% of Prenetics Global shares are owned by company insiders. Comparatively, 17.1% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Prenetics Global has a beta of -0.31, suggesting that its share price is 131% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Profitability

This table compares Prenetics Global and Bio-Rad Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-191.73%	-16.45%	-13.34%
Bio-Rad Laboratories	-30.18%	3.74%	2.65%

Valuation & Earnings

This table compares Prenetics Global and Bio-Rad Laboratories”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prenetics Global	$21.74 million	3.13	-$62.72 million	($3.99)	-1.40
Bio-Rad Laboratories	$2.67 billion	3.27	-$637.32 million	($27.33)	-11.42

Prenetics Global has higher earnings, but lower revenue than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.

Summary

Bio-Rad Laboratories beats Prenetics Global on 9 of the 14 factors compared between the two stocks.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.